氨磺必利与利培酮治疗首发精神分裂症的对照研究

目的比较氨磺必利与利培酮治疗首发精神分裂症的疗效和安全性。方法按就诊先后顺序将首发精神分裂症患者分为研究组和对照组，分别给予氨磺必利和利培酮治疗8周。于治疗前及治疗后第4、8周末采用阳性与阴性综合征量表（PANSS）评定患者的疗效，以治疗中需处理的不良反应症状量表（TESS）评定患者的不良反应。结果治疗后第4、8周末，两组PANSS量表总分及分量表评分较治疗前均有显著降低（P〈0．05，P〈0．01）；研究组有效率93．8％，显效率71．9％；对照组有效率为90．6％，显效率68．8％，两组比较无显著性差异（P〉0．05）。研究组和对照组药物不良反应均较少。结论氨磺必利是一种安全有效的抗精神病药物，对治疗首发精神分裂症疗效与利培酮相当。

Control study of the efficiency of amisulpride vs. risperidone in the treatment of first-episode schizophrenia.

Objective To compare the efficiency and safety of amisulpride vs. risperidone in the treatment of firstepisode schizophrenia. Methods 64 patients with first-episode schizophrenia were randomly divided into study group （32 cases） treated with amisulpride and control group （32 cases） treated with risperidone for 8 weeks. All patients were assessed with Postive and Negative Syndrome Scale （PANSS） at the baseline and at the end of the 4th, 8th week of the treatment to evaluate the efficiency. Treatment Emergent Symptom Scale（TESS） was used to eValuate the side effects. Results Total score and factor scores of PANSS in both groups decreased significantly at the end of the 4th and 8th week when compared with the baseline （ P 〈 0.05 or 0.01 ）, The response rate and marked improvement rate was 93.8% and 71.9% respectively in study group, and was 90.6% and 68.8% respectively in control group. There was no significant difference in response rate between the two groups, nor in marked improvement rate （P 〉 0.05 ）. The incidence of side effects was low in both groups. Conclusion Amisulpride is an effective and safe antipsychotic drugs. The efficiency of amisulpride on first-episode schizophrenia is equivalent with risperidone.